**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 72107

**Manuscript Type:** MINIREVIEWS

**Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma**

Hanif H *et al*. AFP and HCC

Hira Hanif, Mukarram Jamat Ali, Ammu T Susheela, Iman Waheed Khan, Maria Alejandra Luna-Cuadros, Muzammil Muhammad Khan, Daryl Tan-Yeung Lau

**Hira Hanif, Mukarram Jamat Ali, Iman Waheed Khan, Maria Alejandra Luna-Cuadros, Muzammil Muhammad Khan, Daryl Tan-Yeung Lau,** Liver Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, United States

**Ammu T Susheela,** Internal Medicine, Loyola MacNeal Hospital, Berwyn, PA 60402, United States

**Author contributions:** Hanif H and Ali MJ contributed equally; Lau DTY provided the concept and direction of the review, the learning points and the editing of the manuscript; Khan MM, Hanif H, Ali MJ, Susheela AT, and Luna-Cuadros MA reviewed the literature and wrote the first manuscript draft; Khan IW and Ali MJ contributed to the addition of literature, revision and edition of the final manuscript; Khan MM and Lau DTY are joint senior authors.

**Corresponding author: Daryl Tan-Yeung Lau, MD, MSc, Associate Professor,** Liver Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis St. Liver Research Center, Suite 4A, Boston, MA 02215, United States. dlau@bidmc.harvard.edu

**Received:** October 4, 2021

**Revised:** November 26, 2021

**Accepted: December 31, 2021**

**Published online:**

**Abstract**

Alpha-fetoprotein (AFP) is an oncofetal glycoprotein that has been used as a tumor marker for hepatocellular carcinoma (HCC) in combination with ultrasound and other imaging modalities. Its utility is limited because of both low sensitivity and specificity, and discrepancies among the different methods of measurements. Moreover, its accuracy varies according to patient characteristics and the AFP cut-off values used. Combination of AFP with novel biomarkers such as AFP-L3, Golgi specific membrane protein (GP73) and des-gamma-carboxyprothrombin significantly improved its accuracy in detecting HCC. Increased AFP level could also signify severity of hepatic destruction and subsequent regeneration and is commonly observed in patients with acute and chronic liver conditions and cirrhosis. Hereditary and other non-hepatic disorders can also cause AFP elevation.

**Key Words:** Alpha-fetoprotein; Hepatocellular carcinoma; Alpha-fetoprotein-L3; Cirrhosis; Tumor markers; Hereditary persistence of alpha-fetoprotein

Hanif H, Ali MJ, Susheela AT, Khan IW, Luna-Cuadros MA, Khan MM, Lau DTY. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. *World J Gastroenterol* 2022; In press

**Core Tip:** Alpha-fetoprotein has been used commonly as a biomarker for hepatocellular carcinoma (HCC) surveillance. Its sensitivity and specificity can be affected by the assay methods, patient characteristics and severity of the underlying liver conditions. Combination with other novel markers has shown promising results. Algorithms integrating these serum markers with noninvasive diagnostic imaging modalities are essential for the accurate and timely diagnosis of HCC.

**INTRODUCTION**

During fetal and neonatal life, alpha-fetoprotein (AFP)is produced by yolk sac, fetal liver and gastrointestinal tract. Only a trace amount of AFP can be measured in adults due to its rapid decline in adults[1-4]. The use of AFP as a tumor marker for hepatocellular carcinoma (HCC) was first proposed in 1960s. The utility of AFP as a surveillance and diagnostic test has been criticized due to both low sensitivity and specificity. AFP, however, continues to play a significant role for HCC surveillance in combination with ultrasound (US) and other imaging modalities[5-8]. This review focused on both the clinical roles and limitations of AFP. In addition, the patterns of AFP elevation in various non-HCC etiologies were discussed.

**Biology of AFP**

AFP is an oncofetal glycoprotein consisting of a single polypeptide chain of approximately 600 amino acids and nearly 4% carbohydrate. With molecular weight of 67500 dalton, it is a negatively charged protein with an isoelectric point of pH 4.57 and displays several charge isomers by extended agarose gel electrophoresis[1,2]. During the first trimester, AFP is mainly produced by yolk sac. After the atresia of yolk sac by 11-12 wk, fetal liver becomes the predominant source of AFP. A trace amount is also produced by the gastrointestinal tract of the fetus[1]. AFP in fetal serum can be detected as early as 29 d after conception and reaches its peak value of 3.0 × 106 ng/mL by 14th week of gestation. It declines to 2.0 × 105–3.0 × 105 ng/mL by week 32 and further decreases to 20-120 ng/mL at term[3]. By six months of life, serum AFP level is approximately 30 ng/mL. Thereafter, it is detectable between 3 and 15 ng/mL in adulthood[3,4].

AFP belongs to the family of serum albumin and the genes of which are present on the chromosome 4. It shares structure and physiochemical properties with its family members namely albumin, vitamin D-binding protein and afamin[9]. As both albumin and AFP show significant amino acid homologies, AFP is suggested to be an embryonic analogue of albumin[10]. Furthermore, because of its similarity to albumin, it has been postulated that AFP could be a carrier protein. In addition, its role as an immune-regulator and as a carrier protein for bilirubin has also been suggested[11].

AFP, being a principal serum binding protein in the fetus, plays a vital role in carrying various ligands such as fatty acids, hormones, minerals and bilirubin[12]. Though it performs many physiological functions during fetal development, elevated levels in adults are frequently observed in liver carcinogenesis and various disease processes[13-15]. Many biologic studies support the pro-oncogenic as well as anti-apoptotic effects of AFP. AFP can stimulate cell proliferation, cell motility and invasive properties of HCC cell lines and there is evidence that apoptosis of cancer cells could be achieved by blocking AFP[16,17]. On the other hand, a number of cancerous and non- cancerous causes involving both the liver and other organs can also lead to AFP elevation. AFP, therefore, is a non-specific marker of HCC[7] (Table 1).

**How is AFP Measured?**

AFP was originally measured by immunoelectophoresis, but this method was not very sensitive. In the 1970s and 1980s, new techniques such as radioimmunoassay and enzyme immunoassays were used. Subsequently, a quantitative automated chemiluminescent enzyme immunoassay was developed, which replaced and refined the previous clinical assays[18,19]. In this method, the serum sample is placed on a magnetic plate which is already bound by an anti-AFP antibody. A second chemiluminescent detection antibody, added to the same magnetic plate, then binds to all the AFP that is present in excess. All the unbound detection antibody is washed off and an organic substrate called as developer is added which emits light and become luminescent (Figure 1A). A chemiluminometer is used to detect the antibody, and quantification of the results is done against the known AFP standards. However, measurement interference may occur. In a single step method of AFP detection, sometimes interfering antibodies would bind to both the capture and detect antibodies leading to a false positive result (Figure 1B). Conversely, the interfering antibodies may blind to the reagents and inhibiting the proper interaction of AFP with the specific anti-AFP antibodies[20] (Figure 1C).

***AFP as a diagnostic marker for HCC***

The association between AFP and HCC is well recognized; however, the sensitivity and specificity of the AFP assay varies according to patient characteristics, design of the study, and the AFP cut-off values used[21,22] (Table 2). A systematic review of studies using AFP at a threshold value of 20 ng/mL in patients with cirrhosis, the sensitivity and specificity of detecting HCC were 41%-65% and 80%-94%, respectively[22]. Lowering the cut-off can increase the sensitivity of AFP but at the cost of higher false positives. By increasing the AFP value from 20 to 50 ng/mL, the specificity increased to 96% with a positive predictive value of 75% but sensitivity was reduced to 47%[23]. AFP values also vary according to the tumor size. The correlation of AFP to the size of the tumor was evaluated by Saffroy *et al*[24]*.* The bigger tumors generally had higher AFP values. The sensitivity of AFP, therefore, decreased from 52% for HCC > 3 cm to 25% for those < 3 cm in diameter[24].

For AFP-producing HCC, AFP plays an important role in initiating monitoring and terminating HCC therapy. A complete response of the treatment can be expected if preceding levels of AFP decrease to normal on follow ups. AFP, however, cannot be applied to monitor treatment response if its levels were not elevated prior to treatment[25-27]. Approximately one-third of the patients with HCC have no AFP elevation[28]. Nomura *et al*[29] characterized those HCCs with low or no elevation of AFP. These patients generally have favorable prognosis with low probability of HCC recurrence and improved survival as compared to those with elevated AFP levels[29,30]. In a large retrospective study including 1800 patients with HCC, 42% had AFP < 20 ng/mL whereas 16% had AFP levels between 20 and 100 ng/mL. Thus, a total of 58% had AFP < 100 ng/mL. The authors observed that 67% of patients with HCC smaller than 5 cm had AFP ≤ 100 ng/mL *vs* only 49% of the patients with HCC larger than 5 cm had AFP ≤ 100 ng/mL. In addition, HCCs without AFP elevation (≤ 100 ng/mL) were less likely to develop portal vein thrombosis[31].

***AFP-L3 and other HCC biomarkers***

Based on the binding capacity of AFP to lens culinaris agglutinin (LCA), three separated bands of AFP glycoforms can be identified with the Western blotting. These are AFP-L1 (non-binding), AFP-L2 (intermediate binding) and AFP-L3 (LCA-reactive). AFP-L1 generally correlates with hepatic inflammation in chronic hepatitis while AFP-L3 is more specific for HCC. AFP-L2 is derived from yolk sac and is detectable in the maternal serum during pregnancy[32] (Table 3).

AFP-L3 is calculated as a fraction of AFP-L3 to total AFP. The cut-off values most commonly used for a positive AFP-L3 test for patients with HCC is 10% though levels above 15% are more specific[33]. It is secreted in the initial tumor stages and thus can be used as an early HCC diagnostic marker[32,34]. AFP-L3 level can also distinguish the histological differentiation of tumors[25]. In patients with total AFP level ≤ 200 ng/mL, AFP-L3 specificity may reach 100% for HCC if it increases more than 35% of the total AFP[35]. In a large multicenter prospective study of hepatitis C virus related HCC, the specificity of AFP-L3 was observed to be 92% but its sensitivity was fairly low at 37%, irrespective of the tumor stage[36]. On the contrary, a number of recent studies reported a much higher sensitivity of AFP-L3 for diagnosing HCC[37-39]. Ibrahim *et al*[39] evaluated the diagnostic efficacy of AFP-L3 among 20 healthy individuals, 40 patients of chronic active hepatitis and 40 HCC patients with underlying chronic hepatitis B (CHB) or C. Among the HCC patients, 30 (75%) had tumor size > 5 cm. At a cut-off point of > 12.3 ng/mL, AFP-L3 was 100% accurate in diagnosing the HCC[39]. In a study by Ibrahim *et al*[39], 20 healthy individuals, 20 chronic liver disease patients and 40 patients HCV-induced HCC were included in the analysis. A large proportion (65%) of the HCC patients had advanced stage of HCC. By using a cut-off value of 23 ng/mL, AFP-L3 had a sensitivity of 97.5% and specificity of 100% in predicting HCC at[37]. Cerban *et al*[38] investigated the diagnostic performance of AFP, AFP-L3, PIVKA-II and GPC-3 for HCC in a cohort including 52 cirrhotic and 101 HCC patients. AFP-L3 at a cut-off point of > 13.5 ng/mL was found to have a higher sensitivity of 84.7%, compared to other biomarkers[38]. The sensitivity of AFP-L3 for HCC detection can be affected by its cut-off values, as well as the tumor size and stage[40]. Data suggested that AFP-L3 could potentially be a valuable prognostic tool. The persistent elevation of AFP-L3 after HCC therapy was found to be associated with shorter survival[25].

Recently, a highly-sensitive AFP-L3 or hs-AFP-L3 was developed. Toyoda el al. determined the performance of hs-AFP-L3 among patients with 44 patients with chronic hepatitis or cirrhosis, and 54 patients with HCC. The sensitivity and specificity of hs-AFP-L3 were 84.9% and 88.6%, respectively[41].

Since both total AFP and AFP-L3 have limitations for the detection of HCC, studies have been conducted to combine AFP and AFP-L3 with other novel immunoassays to improve their performance. Des-gamma-carboxyprothrombin (DCP), also known as PIVKA-II (Protein Induced by vitamin K absence or antagonist-II), is a promising HCC biomarker. PIVKA-II is an abnormal product of liver carboxylation that reflects oncogenesis and HCC progression and is undetectable in healthy patients[25,42].

A systematic review noted that AFP, AFP-L3 combined with DCP enhanced their individual HCC predictive values with pooled sensitivity and specificity of 88% and 79%, respectively[43,44]. Since 2002, Japan has included these 3 biomarkers in their HCC surveillance programs and they noted improved rates of early HCC identification and prognosis[43]. When applying the GALAD score (age, sex, AFP, AFP-L3 and DCP), the HCC diagnostic accuracy was even higher [area under curve (AUC) 0.976][45,46]. A recent meta-analysis reported that AFP combined with GP73 (a Golgi specific membrane protein found in epithelial cells of bile ducts) has favorable sensitivity (84%) and specificity (92%) in diagnosing HCC with an AUROC value of 0.93[47].

Lately, a new HCC diagnostic marker, the long noncoding RNAs (lncRNAs), was developed[48]. LncRNAsare transcribed by RNA polymerase II and play a role in the regulation of transcription and translation of proteins. Small extracellular vesicles (EV) transfer proteins, DNA, and RNA between tumor and nontumor cells. The dysregulated lncRNAs including EV-derived lncRNAs contribute to HCC progression and metastasis. EV-derived lncRNAs are, therefore, potential novel serum biomarkers. Kim *et al*[48] evaluated LINC00853, an EV-derived lncRNA in 90 patients with HCC and 92 without HCC in a cohort study. The AUROC of LINC00853 was 0.935 for identifying all-stage HCC and 0.969 for detecting early-stage HCC. These results were significantly better compared to AFP[48]. In another study by Yu *et al*[49] reported that the combination of AFP with 2-lncRNA had a higher discriminative power than that of AFP alone in the diagnosis of HCC[49].

**AFP elevation in liver diseases and cirrhosis**

Rise in AFP has been recorded in different chronic liver diseases without HCC and other malignancies, hence, the results of AFP levels should be interpreted with caution[50]. AFP is known to have a role in liver regeneration, inflammation and liver fibrosis. Less pronounced AFP elevation > 10 ng/mL has been reported in 15%-58% of chronic hepatitis and 11%-47% of cirrhosis[51]. The usual cut off for differentiating benign *vs* malignant liver conditions was at 500 ng/mL but can be variable[52]. Studies have reported a progressive rise in serum AFP levels with increased histological severity from inflammation to cirrhosis to HCC[53].

**Acute hepatitis**

The degree of AFP elevation in acute hepatitis is related to the severity of hepatic destruction[50,54]. The levels range from 10 ng/mL-1000 ng/mL with occasional higher value from 3000 to 7190 ng/mL has been reported. Among children with acute hepatitis B, AFP was detected within 1 wk of the onset of clinical hepatitis and returned to normal by the time of recovery with loss of HBsAg[55]. The possible mechanisms of AFP elevation include acute phase reaction to the liver injury, hepatocyte regeneration, or viral control or mediated AFP synthesis[56]. AFP elevation after significant alanine aminotransferase (ALT) elevation is most likely due to liver regeneration and there is generally a latent period of 5-16 d[57]. AFP generally peaks at a time when liver destruction is subsiding and hepatic remodeling begins[57]. Hence, the highest level of AFP in acute hepatitis generally occurs during the recovery phase of illness and is an indicator of the liver regenerative process[58].

**CHB**

Elevated AFP levels are frequently observed during the course of CHB without HCC. The commonest cause of AFP elevation was the exacerbation of the underlying liver disease with or without changes in the status of hepatitis B virus (HBV) replication[41,52]. High AFP levels associated with hepatitis flare were also found to be predictive of HBeAg to anti-HBe seroconversion[59,60]. AFP levels usually decrease within 12 mo on antiviral therapy[61]. Kim *et al*[61] reported that AFP normalization (< 20 ng/mL) was achieved in 89.5% of treated patients but remained abnormal in 40.6% of antiviral treatment naïve patients[61].

Persistent elevation of AFP > 100 ng/mL without a parallel increase in ALT level was reported to be a predictor of HCC with a sensitivity of 98.7% and specificity of 66.7%[59]. Yuan *et al*[62] conducted a retrospective study of 302 treatment naive CHB patients with AFP positive status. After antiviral therapy, they found that there was a 6.35-fold increased HCC risk among those with persistently elevated AFP compared to those with normalized AFP levels[62].

In a metanalysis, Peng *et al*[63] concluded that among HBV–related HCCs with low AFP levels, circulating miRNAs could be potential valuable biomarkers. For patients with AFP levels < 400 ng/mL, miR-125b and miR-205 demonstrated a sensitivity of 90% while combination of miR-15b and miR-130b had > 90% sensitivity and specificity. For AFP < 20 ng/mL, miR-26a, 27a, 7b and combination of miR-122 and miR-7b exhibited a sensitivity of 80% while combination of mir-29a, 29c, 133a, 143, 145, 192 and 505 produced a specificity of > 80%. Additionally, the combination of miR-15b and miR-130b showed high diagnostic accuracy with sensitivity and specificity exceeding 90%. For differentiating HCC patients with low AFP levels (< 20 ng/mL) from non-HCC patients, the overall sensitivity and specificity of miRNAs were 0.85 and 0.74, respectively with AUC of 0.88 (95%CI: 0.85–0.90). For patients with AFP < 400ng/mL, the overall sensitivity and specificity were 0.84 and 0.76 with AUC of 0.88 (95%CI: 0.84–0.90). Hence, miRNAs are attractive HCC markers to detect HBV-associated HCC with low AFP levels[63].

Dickkopf WNT signaling pathway inhibitor 1 (DKK-1) is a glycoprotein that is expressed in various malignancies. Shen *et al*[64] conducted a study on 424 HCC, 98 CHB, 96 cirrhosis and 213 healthy controls and measured their DKK-1 Levels. The diagnostic cut-off was established at 2.153 ng/mL. DKK-1 proved useful in the detection of AFP-negative HCC with 70.4% sensitivity and 90.0% specificity. These values were validated in another cohort. When combined with AFP, DKK-1 increased detection rate of early-stage HCC with 73.1% sensitivity and 90.0% specificity. Additionally, elevated DKK-1 Levels can help differentiate HCC from other liver diseases such as CHB and cirrhosis with 69.1% sensitivity and 84.7% specificity[64,65].

Hepatitis B flare is defined as an abrupt elevation of serum ALT to 5 times the ULN or greater than 3-fold increase from baseline[66]. During hepatitis flare, peak AFP level was usually observed 1-2 wk after peak ALT rise. Significant AFP elevation to > 2500 ng/mL had been documented with hepatitis flare. The normalization of AFP might take up to 3-12 mo[66].

The presentation varies from asymptomatic to overt hepatitis with decompensation and liver failure. AFP elevation was noted in 25%-30% of the patients with hepatitis flares. A study reported the annual incidence of hepatitis flares to be 27% in HBeAg-positive patients and 10% in HBeAg-negative patients with a mean follow-up period of 2 years. Chang *et al*[67] reported that patients with AFP > 100 ng/mL during flare cleared HBeAg at a rate of 31% in 3 mo, 62% in 12 mo and 72% in 18 mo. In contrast, the corresponding HBeAg clearance rates for those with AFP < 100 ng/mL were only 4%, 15% and 19% in 3, 12 and 18 mo respectively[67]. Patients with bridging hepatic necrosis (BHN) had increased activation of the AFP-producing oval cell. BHN was noted in 80% of the cases with AFP levels > 100 mg/dL[53]. BHN, AFP > 100 ng/mL and decreasing HBV DNA titers were identified as good prognostic indicators of an effective immune control with HBV DNA suppression and/or HBeAg clearance.

Severe and repeated hepatitis flares could also lead to development of cirrhosis or hepatic decompensation. Patients with severe hepatitis flare with BHN or AFP > 100 ng/mL but fail to suppress HBV DNA should be treated promptly with antiviral therapy.

**Chronic hepatitis C**

AFP elevation is more greatly associated with HCV-associated HCC than HBV-associated HCC[64]. The incidence of elevated AFP inchronic hepatitis C (CHC) patients range from 10%-43%[61]. Elevated AFP > 20 ng/dL in CHC is associated with female gender, black race, increased age, genotype 1b, low albumin level, elevated aspartate aminotransferase (AST), elevated AST/ALT ratio, low platelet, prolonged PT, and increased ferritin levels[68,69]. Yang *et al*[70] evaluated 279 CHC patients and found no correlation between AFP and the levels of HCV RNA[70]. In the HALT C (Hepatitis C Antiviral Long-term Treatment) study, Di Bisceglie *et al*[71] observed AFP > 20 ng/mL in 16.6% of patients without HCC; it was associated with cirrhosis, female and Black patients[71]. Black patients with CHC tend to have higher AFP elevation compared to other racial groups[71]. Generally, HCV-related HCC does not have significant AFP elevation. Thus, AFP has especially low sensitivity to identify HCC in Black populations[71].

Fouad *et al*[72] reported that sustained virological response with direct-acting antiviral agents (DAA) therapy was associated with a significant reduction in serum AFP and might be used as a predictor of treatment response[72]. In another study, 60% of the DAA treated patients normalized AFP compared to only 23% without therapy[61].

Therapeutic phlebotomy has also been reported to reduce AFP levels in CHC[44]. It has been postulated that iron mediated oxidative stress is associated with hepatic injury; iron depletion decreases the oxidative stress and indirectly lowers the AFP level[73].

**Nonalcoholic fatty liver disease**

Nonalcoholic fatty liver disease (NAFLD) has become the most common liver disease in the Western world with about 10%-30% progress to cirrhosis[74]. It is estimated that 6 million people in the United States have NASH with 1%-2% incidence of HCC annually. Published reports estimated that over 25% of NASH-related HCC occurred in patients without cirrhosis. With the high prevalence of NAFLD, risk stratification is essential to implement HCC surveillance programs[75]. Currently, no surveillance of NALFD patients for HCC is recommended by AASLD[76]. However, it has been suggested that NAFLD patients with cirrhosis or possible fibrosis or diabetes mellitus should have 6 monthly surveillances *via* ultrasound (US) and tumor markers (AFP, AFP-L3 and DCP). Abdominal fat can be a hindrance, hence, patients with obesity can be alternatively surveilled using CT-Scan or magnetic resonance imaging[77].

An association between AFP elevation and NAFLD was first established by Babalı *et al*[78] in 2009. This study demonstrated a significant increase in AFP levels in patients suffering from NAFLD (4.09 ± 1.68) in comparison to the control group (2.95 ± 0.41) with *P* value < 0.05.Additionally, three subgroups of NAFLD were created based on the liver ultrasonography findings with presence of hepatorenal contrast or bright liver corresponding to grade 1, both hepatorenal contrast and bright liver signifying grade 2, and both pre-mentioned findings with bright liver being severe representing grade 3. The results showed a significant increase in AFP in grade 3 NAFLD (5.43 ± 1.51) in comparison to grade 2 (3.97 ± 1.45) and grade 1 (2.92 ± 1.06) with a *P* value of 0.001. Triglyceride, cholesterol, low density lipoprotein, high-density lipoprotein, glucose and ALT levels were not significantly different in these groups[78].

Best *et al*[79] published a case control study on German centers in 2020 describing the relationship between HCC and NASH using AFP, AFP-L3, DCP and the GALAD score for assessment. 125 NASH patients with HCC and 231 NASH control patients without HCC were taken. The GALAD score recognized patients with HCC at any stage with an AUC of 0.96 which was superior to AUC of AFP (AUC 0.88), AFP-L3 (AUC 0.86) and DCP (AUC 0.87) levels with *P* < 0.001 at a cut off about -0.63. The sensitivity was 84.8% and specificity was 95.2% at this cut off. They also conducted Japanese cohort study on 392 patients with NAFLD out of which 28 patients developed HCC. The mean GALAD score in these 28 patients predicted occurrence of HCC 1.5 years before its diagnosis. GALAD score was considerably higher in these patients compared to NASH patients who did not develop HCC[79].

**Early *vs* advanced liver cirrhosis with decompensation**

Arrieta *et al*[80] reported that AFP ≥ 200 and 400 ng/mL had a sensitivity of 36.3% and 20.2% in determining HCC with 100% specificity. Improved method of analysis using progressive elevation of AFP ≥ 7 ng/mL/mo among cirrhotic patients increased the sensitivity to 71.4% with 100% specificity. This method was successful even when AFP values were below 200 ng/mL[80].

AFP can be elevated in patients with CHC or cirrhosis without any evidence of HCC[81]. A persistent AFP value of 17.8 ng/mL was noted to have a 98.6% specificity, 35% sensitivity and a positive predictive value of 97.7% in identifying patients with cirrhosis[82]. Sudden fluctuations in AFP levels in patients with cirrhosis can be indicative of hepatitis flare, deterioration of liver disease and development of HCC[83]. AFP has been applied routinely for HCC surveillance in cirrhotic patients. Harada *et al*[83] showed that 40% of cirrhotic patients had AFP levels > 20 mg/dL[83]. Manuc *et al*[84] reported in a study of 2068 CHC patients with cirrhosis, 30.1% without HCC had AFP > 15 ng/mL due to advanced age, severe liver injury with raised AST and ALT levels and low platelets[84].

In patients with cirrhosis, both the sensitivity and specificity of AFP for detection of early-stage HCC diagnosis can be enhanced by combining it with US. In a meta-analysis, the pooled sensitivity of AFP and US for any stage and early-stage HCC were 95% (83%-100%) and 60% (45%–74%) respectively, compared to only 72% (56%–86%) and 40% (22%–58%) for US only[85]. Surveillance with AFP and ultrasonography in cirrhotic patients having an annual risk of HCC > 0.4% is cost-effective[86].

There are many risk scores that have been developed to predict HCC development among patients with chronic hepatitis and cirrhosis. However, many of them have not been standardized or carefully validated in different patient populations. Ideally, HCC prediction models should be developed for treated and untreated patients taking into account the patient ethnicity, significant comorbid conditions and ideally the molecular biomarkers[87].

**Persistent AFP elevation in the absence of liver disease**

AFP is an important screening test for HCC and is also used in the diagnostic evaluation of other hepatic and non-hepatic conditions. Persistent AFP elevation has also been reported in patients without malignant or nonmalignant conditions. Hereditary persistence of AFP (HPAFP), a benign autosomal dominant disorder with no apparent disease or abnormality, should be considered as one of the differential diagnoses in patients with unclear etiology of persistent AFP elevation[88]. HPAFP is a rare condition with only 20 reported cases in the literature[89]. In contrast to malignant tumors with AFP usually > 500 ng/mL, the AFP concentration in HPAFP is mostly below 200 ng/mL, but levels up to 1500 ng/mL have been reported in some cases[88,90,91]. The molecular mechanism of HPAFP can differ in unrelated families. Specific heterozygous point mutations are frequently found in the promoter region of the AFP gene related to hepatocyte nuclear factor 1 (HNF1) binding sites[92,93]. These mutations usually result in an increased affinity for HNF1 and subsequently lead to increased AFP promoter activity and AFP gene transcription[94]. Two-point mutations have been identified; the upstream substitution of cytosine (C) with adenosine (A) at amino acid position of 55 (-55 C > A) in the proximal HNF-1 binding site and upstream mutation caused by the substitution of Guanine (G) by Adenosine (A) at position 119 (-119 G > A) in the distal HNF-1 binding site[95,96]. The first case of HPAFP was reported in 1984 by Greenberg *et al*[91] in a Scottish family where a 38-year-old woman was noted to have persistently elevated AFP during post-partum[91]. The AFP concentration of her amniotic fluid was normal and HPAFP was later confirmed by evaluating serum AFP levels and molecular testing in family members. In another report of 20 HPAFP cases, 2 patients underwent unnecessary surgery and 3 had unnecessary chemotherapy due to their persistently elevated AFP[96]. Though rare, hereditary causes should be considered in patients with unexplained and persistent AFP elevation. In a recent study by Jeon *et al*[89] on 4 Korean patients with persistently elevated AFP levels from 12.1 to 186.1 ng/mL for > 1 year, 1 patient was found to have a hereditary cause by pedigree analysis even though the typical mutation of the AFP gene in the promoter region was absent. This case elucidated the heterogeneous nature of persistent AFP elevation and HPAFP is not always the result of mutation in the AFP transcription regulatory regions[89].

**CONCLUSION**

AFP has been used for HCC surveillance widely in clinical practice. It, however, has limited sensitivity and specificity for HCC detection, and a proportion of patients with advanced HCC do not have AFP secretion. Moreover, patients with chronic liver diseases, especially those with cirrhosis are commonly identified with persistent AFP elevation without radiological evidence of HCC. For all these reasons, AFP is not recommended to be used as a sole marker alone for HCC surveillance. The diagnostic potential of AFP for early diagnosis of HCC can be enhanced by combining it with other novel diagnostic markers such as AFP-L3, PIVKA-II, and GP73. Although many have already endorsed diagnostic value, large number of multicenter studies encompassing larger cohorts and long-term assessment are required to confirm clinical utility. Additionally, algorithms integrating these serum markers with noninvasive diagnostic imaging modalities are needed to be developed for the early and accurate diagnosis of HCC.

**REFERENCES**

1 **Gitlin D**, Perricelli A, Gitlin GM. Synthesis of -fetoprotein by liver, yolk sac, and gastrointestinal tract of the human conceptus. *Cancer Res* 1972; **32**: 979-982 [PMID: 4111729]

2 **Yachnin S**. The clinical significance of human alpha-fetoprotein. *Ann Clin Lab Sci* 1978; **8**: 84-90 [PMID: 76458]

3 **Masseyeff R**, Gilli J, Krebs B, Calluaud A, Bonet C. Evolution of alpha-fetoprotein serum levels throughout life in humans and rats, and during pregnancy in the rat. *Ann N Y Acad Sci* 1975; **259**: 17-28 [PMID: 54020 DOI: 10.1111/j.1749-6632.1975.tb25398.x]

4 **Ball D**, Rose E, Alpert E. Alpha-fetoprotein levels in normal adults. *Am J Med Sci* 1992; **303**: 157-159 [PMID: 1375809 DOI: 10.1097/00000441-199203000-00004]

5 **Thompson Coon J**, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, Jackson S, Ryder S, Price A, Stein K. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. *Health Technol Assess* 2007; **11**: 1-206 [PMID: 17767898 DOI: 10.3310/hta11340]

6 **Marrero JA**, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology* 2018; **68**: 723-750 [PMID: 29624699 DOI: 10.1002/hep.29913]

7 **Omata M**, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. *Hepatol Int* 2017; **11**: 317-370 [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9]

8 **Kim DY**, Han KH. Epidemiology and surveillance of hepatocellular carcinoma. *Liver Cancer* 2012; **1**: 2-14 [PMID: 24159567 DOI: 10.1159/000339016]

9 **Terentiev AA**, Moldogazieva NT. Alpha-fetoprotein: a renaissance. *Tumour Biol* 2013; **34**: 2075-2091 [PMID: 23765762 DOI: 10.1007/s13277-013-0904-y]

10 **Ruoslahti E**, Terry WD. alpha foetoprotein and serum albumin show sequence homology. *Nature* 1976; **260**: 804-805 [PMID: 57576 DOI: 10.1038/260804a0]

11 **Crandall BF**. Alpha-fetoprotein: a review. *Crit Rev Clin Lab Sci* 1981; **15**: 127-185 [PMID: 6169490 DOI: 10.3109/10408368109105870]

12 **Murray MJ**, Nicholson JC. α-Fetoprotein. *Arch Dis Child Educ Pract Ed* 2011; **96**: 141-147 [PMID: 21613305 DOI: 10.1136/adc.2011.213181]

13 **Bloomer JR**, Waldmann TA, McIntire KR, Klatskin G. alpha-fetoprotein in noneoplastic hepatic disorders. *JAMA* 1975; **233**: 38-41 [PMID: 48562 DOI: 10.1001/jama.233.1.38]

14 **Shen WF**, Zhong W, Xu F, Kan T, Geng L, Xie F, Sui CJ, Yang JM. Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma. *World J Gastroenterol* 2009; **15**: 5976-5982 [PMID: 20014463 DOI: 10.3748/wjg.15.5976]

15 **Schneider DT**, Calaminus G, Göbel U. Diagnostic value of alpha 1-fetoprotein and beta-human chorionic gonadotropin in infancy and childhood. *Pediatr Hematol Oncol* 2001; **18**: 11-26 [PMID: 11205836 DOI: 10.1080/088800101750059828]

16 **Sauzay C**, Petit A, Bourgeois AM, Barbare JC, Chauffert B, Galmiche A, Houessinon A. Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma. *Clin Chim Acta* 2016; **463**: 39-44 [PMID: 27732875 DOI: 10.1016/j.cca.2016.10.006]

17 **Wang X**, Wang Q. Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity. *Can J Gastroenterol Hepatol* 2018; **2018**: 9049252 [PMID: 29805966 DOI: 10.1155/2018/9049252]

18 **Law SW**, Dugaiczyk A. Homology between the primary structure of alpha-fetoprotein, deduced from a complete cDNA sequence, and serum albumin. *Nature* 1981; **291**: 201-205 [PMID: 6164927 DOI: 10.1038/291201a0]

19 **Nishizono I**, Iida S, Suzuki N, Kawada H, Murakami H, Ashihara Y, Okada M. Rapid and sensitive chemiluminescent enzyme immunoassay for measuring tumor markers. *Clin Chem* 1991; **37**: 1639-1644 [PMID: 1716538]

20 **Shah PA**, Onken A, Ishtiaq R, Maqsood MH, Patel SS, Campoverde Reyes KJ, Herskovits AZ, Lau DTY. A challenging case of alpha-fetoprotein-result discrepancies in a patient with chronic hepatitis B. *Gastroenterol Rep (Oxf)* 2020; **8**: 484-486 [PMID: 33447392 DOI: 10.1093/gastro/goaa052]

21 **Abelev GI**, Perova SD, Khramkova NI, Postnikova ZA, Irlin IS. Production of embryonal alpha-globulin by transplantable mouse hepatomas. *Transplantation* 1963; **1**: 174-180 [PMID: 14010646 DOI: 10.1097/00007890-196301020-00004]

22 **Gupta S**, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. *Ann Intern Med* 2003; **139**: 46-50 [PMID: 12834318 DOI: 10.7326/0003-4819-139-1-200307010-00012]

23 **Gambarin-Gelwan M**, Wolf DC, Shapiro R, Schwartz ME, Min AD. Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. *Am J Gastroenterol* 2000; **95**: 1535-1538 [PMID: 10894592 DOI: 10.1111/j.1572-0241.2000.02091.x]

24 **Saffroy R**, Pham P, Reffas M, Takka M, Lemoine A, Debuire B. New perspectives and strategy research biomarkers for hepatocellular carcinoma. *Clin Chem Lab Med* 2007; **45**: 1169-1179 [PMID: 17635075 DOI: 10.1515/CCLM.2007.262]

25 **Bertino G**, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. *Semin Oncol* 2012; **39**: 410-433 [PMID: 22846859 DOI: 10.1053/j.seminoncol.2012.05.001]

26 **Luo P**, Wu S, Yu Y, Ming X, Li S, Zuo X, Tu J. Current Status and Perspective Biomarkers in AFP Negative HCC: Towards Screening for and Diagnosing Hepatocellular Carcinoma at an Earlier Stage. *Pathol Oncol Res* 2020; **26**: 599-603 [PMID: 30661224 DOI: 10.1007/s12253-019-00585-5]

27 **Sonbol MB**, Riaz IB, Naqvi SAA, Almquist DR, Mina S, Almasri J, Shah S, Almader-Douglas D, Uson Junior PLS, Mahipal A, Ma WW, Jin Z, Mody K, Starr J, Borad MJ, Ahn DH, Murad MH, Bekaii-Saab T. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis. *JAMA Oncol* 2020; **6**: e204930 [PMID: 33090186 DOI: 10.1001/jamaoncol.2020.4930]

28 **Breborowicz J**. Microheterogeneity of human alphafetoprotein. *Tumour Biol* 1988; **9**: 3-14 [PMID: 2452473 DOI: 10.1159/000217540]

29 **Nomura F**, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. *Cancer* 1989; **64**: 1700-1707 [PMID: 2477133 DOI: 10.1002/1097-0142(19891015)64:8<1700::aid-cncr2820640824>3.0.co;2-z]

30 **Agopian VG**, Harlander-Locke MP, Markovic D, Zarrinpar A, Kaldas FM, Cheng EY, Yersiz H, Farmer DG, Hiatt JR, Busuttil RW. Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein. *JAMA Surg* 2017; **152**: 55-64 [PMID: 27706479 DOI: 10.1001/jamasurg.2016.3310]

31 **Carr BI**, Akkiz H, Üsküdar O, Yalçın K, Guerra V, Kuran S, Karaoğullarından Ü, Altıntaş E, Özakyol A, Tokmak S, Ballı T, Yücesoy M, Bahçeci Hİ, Ülkü A, Akçam T, Polat KY, Ekinci N, Şimşek H, Örmeci N, Sonsuz A, Demir M, Kılıç M, Uygun A, Demir A, Delik A, Arslan B, Doran F, Yilmaz S, Tokat Y. HCC with low- and normal-serum alpha-fetoprotein levels. *Clin Pract (Lond)* 2018; **15**: 453-464 [PMID: 29576865 DOI: 10.4172/clinical-practice.1000393]

32 **Taketa K**, Sekiya C, Namiki M, Akamatsu K, Ohta Y, Endo Y, Kosaka K. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. *Gastroenterology* 1990; **99**: 508-518 [PMID: 1694805 DOI: 10.1016/0016-5085(90)91034-4]

33 **Zhou H**, Wang H, Zhou D, Wang H, Wang Q, Zou S, Tu Q, Wu M, Hu H. Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis. *Eur J Cancer* 2010; **46**: 1056-1061 [PMID: 20202823 DOI: 10.1016/j.ejca.2010.02.005]

34 **AlSalloom AA**. An update of biochemical markers of hepatocellular carcinoma. *Int J Health Sci (Qassim)* 2016; **10**: 121-136 [PMID: 27004063]

35 **Leerapun A**, Suravarapu SV, Bida JP, Clark RJ, Sanders EL, Mettler TA, Stadheim LM, Aderca I, Moser CD, Nagorney DM, LaRusso NF, de Groen PC, Menon KV, Lazaridis KN, Gores GJ, Charlton MR, Roberts RO, Therneau TM, Katzmann JA, Roberts LR. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. *Clin Gastroenterol Hepatol* 2007; **5**: 394-402; quiz 267 [PMID: 17368240 DOI: 10.1016/j.cgh.2006.12.005]

36 **Sterling RK**, Jeffers L, Gordon F, Venook AP, Reddy KR, Satomura S, Kanke F, Schwartz ME, Sherman M. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. *Clin Gastroenterol Hepatol* 2009; **7**: 104-113 [PMID: 18849011 DOI: 10.1016/j.cgh.2008.08.041]

37 **Ibrahim AA,** Allah RM, El Hammady AM, Sarhan RS, Khalil MA, Rahman MM. Diagnostic accuracy of lectin-reactive α-fetoprotein (AFP-L3) in the diagnosis of hepatitis C virus-related hepatocellular carcinoma. *Benha Medical J* 2018; **35:** 312 [DOI: 10.4103/bmfj.bmfj\_33\_18]

38 **Cerban R,** Ester C, Iacob S, Ghioca M, Paslaru L, Dumitru R, Grasu M, Constantin G, Popescu I, Gheorghe L. Alpha-fetoprotein, alpha-fetoprotein-L3, protein induced by vitamin K absence, glypican 3 and its combinations for diagnosis of hepatocellular carcinoma. *Surg Gastroenterol* 2019; **24:** 37-44 [DOI: 10.21614/sgo-24-1-37]

39 **Ibrahim HM**, Elghannam MZ, Elkhawaga OAY, El-Sokkary AMA. Evaluation of serum alpha fetoprotein-L3 as an accuracy novel biomarker for the early diagnosis of hepatocellular carcinoma in Egyptian patients. *Saudi J Biol Sci* 2021; **28**: 5760-5764 [PMID: 34588888 DOI: 10.1016/j.sjbs.2021.06.020]

40 **Oka H**, Saito A, Ito K, Kumada T, Satomura S, Kasugai H, Osaki Y, Seki T, Kudo M, Tanaka M; Collaborative Hepato-Oncology Study Group of Japan. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. *J Gastroenterol Hepatol* 2001; **16**: 1378-1383 [PMID: 11851836 DOI: 10.1046/j.1440-1746.2001.02643.x]

41 **Toyoda H**, Kumada T, Tada T, Sone Y, Kaneoka Y, Maeda A. Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC. *Liver Cancer* 2015; **4**: 126-136 [PMID: 26020034 DOI: 10.1159/000367735]

42 **Yu R**, Tan Z, Xiang X, Dan Y, Deng G. Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data. *BMC Cancer* 2017; **17**: 608 [PMID: 28863782 DOI: 10.1186/s12885-017-3609-6]

43 **Wang X**, Zhang Y, Yang N, He H, Tao X, Kou C, Jiang J. Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis. *Biomed Res Int* 2020; **2020**: 5087643 [PMID: 33015170 DOI: 10.1155/2020/5087643]

44 **Lim TS**, Kim DY, Han KH, Kim HS, Shin SH, Jung KS, Kim BK, Kim SU, Park JY, Ahn SH. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. *Scand J Gastroenterol* 2016; **51**: 344-353 [PMID: 26340708 DOI: 10.3109/00365521.2015.1082190]

45 **Caviglia GP**, Abate ML, Petrini E, Gaia S, Rizzetto M, Smedile A. Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection. *Hepatol Res* 2016; **46**: E130-E135 [PMID: 26082262 DOI: 10.1111/hepr.12544]

46 **Zhou L**, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. *World J Gastroenterol* 2006; **12**: 1175-1181 [PMID: 16534867 DOI: 10.3748/wjg.v12.i8.1175]

47 **Fang YS**, Wu Q, Zhao HC, Zhou Y, Ye L, Liu SS, Li XX, Du WD. Do combined assays of serum AFP, AFP-L3, DCP, GP73, and DKK-1 efficiently improve the clinical values of biomarkers in decision-making for hepatocellular carcinoma? A meta-analysis. *Expert Rev Gastroenterol Hepatol* 2021; **15**: 1065-1076 [PMID: 33691550 DOI: 10.1080/17474124.2021.1900731]

48 **Kim SS**, Baek GO, Ahn HR, Sung S, Seo CW, Cho HJ, Nam SW, Cheong JY, Eun JW. Serum small extracellular vesicle-derived LINC00853 as a novel diagnostic marker for early hepatocellular carcinoma. *Mol Oncol* 2020; **14**: 2646-2659 [PMID: 32525601 DOI: 10.1002/1878-0261.12745]

49 **Yu J**, Han J, Zhang J, Li G, Liu H, Cui X, Xu Y, Li T, Liu J, Wang C. The long noncoding RNAs PVT1 and uc002mbe.2 in sera provide a new supplementary method for hepatocellular carcinoma diagnosis. *Medicine (Baltimore)* 2016; **95**: e4436 [PMID: 27495068 DOI: 10.1097/MD.0000000000004436]

50 **Wong RJ**, Ahmed A, Gish RG. Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders. *Clin Liver Dis* 2015; **19**: 309-323 [PMID: 25921665 DOI: 10.1016/j.cld.2015.01.005]

51 **Taketa K**. Alpha-fetoprotein: reevaluation in hepatology. *Hepatology* 1990; **12**: 1420-1432 [PMID: 1701754 DOI: 10.1002/hep.1840120625]

52 **Lok AS**, Lai CL. alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. *Hepatology* 1989; **9**: 110-115 [PMID: 2461890 DOI: 10.1002/hep.1840090119]

53 **Liu YR**, Lin BB, Zeng DW, Zhu YY, Chen J, Zheng Q, Dong J, Jiang JJ. Alpha-fetoprotein level as a biomarker of liver fibrosis status: a cross-sectional study of 619 consecutive patients with chronic hepatitis B. *BMC Gastroenterol* 2014; **14**: 145 [PMID: 25128299 DOI: 10.1186/1471-230X-14-145]

54 **Liaw YF**, Tai DI, Chen TJ, Chu CM, Huang MJ. Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. *Liver* 1986; **6**: 133-137 [PMID: 2427909 DOI: 10.1111/j.1600-0676.1986.tb00279.x]

55 **Pongpipat D**, Suvatte V, Tuchinda M, Assateerawatt A. Occurrence of alpha 1-fetoprotein in acute viral hepatitis in children. *Am J Dis Child* 1979; **133**: 551-552 [PMID: 86295 DOI: 10.1001/archpedi.1979.02130050095020]

56 **Kew MC**, Purves LR, Bersohn I. Serum alpha-fetoprotein levels in acute viral hepatitis. *Gut* 1973; **14**: 939-942 [PMID: 4131854 DOI: 10.1136/gut.14.12.939]

57 **Silver HK**, Deneault J, Gold P, Thompson WG, Shuster J, Freedman SO. The detection of alpha 1-fetoprotein in patients with viral hepatitis. *Cancer Res* 1974; **34**: 244-247 [PMID: 4809461]

58 **Seo SI**, Kim SS, Choi BY, Lee SH, Kim SJ, Park HW, Kim HS, Shin WG, Kim KH, Lee JH, Kim HY, Jang MK. Clinical significance of elevated serum alpha-fetoprotein (AFP) level in acute viral hepatitis A (AHA). *Hepatogastroenterology* 2013; **60**: 1592-1596 [PMID: 24634927]

59 **Song G**, Rao H, Feng B, Wei L. Prediction of spontaneous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients during the immune clearance phase. *J Med Virol* 2014; **86**: 1838-1844 [PMID: 25088043 DOI: 10.1002/jmv.24032]

60 **Liaw YF**, Chu CM, Huang MJ, Sheen IS, Yang CY, Lin DY. Determinants for hepatitis B e antigen clearance in chronic type B hepatitis. *Liver* 1984; **4**: 301-306 [PMID: 6503634 DOI: 10.1111/j.1600-0676.1984.tb00942.x]

61 **Kim CY**, Kim BR, Lee SS, Jeon DH, Lee CM, Kim WS, Cho HC, Kim JJ, Lee JM, Kim HJ, Ha CY, Kim HJ, Kim TH, Jung WT, Lee OJ. Clinical features of hepatitis B and C virus infections, with high α-fetoprotein levels but not hepatocellular carcinoma. *Medicine (Baltimore)* 2017; **96**: e5844 [PMID: 28079817 DOI: 10.1097/MD.0000000000005844]

62 **Yuan G**, Zhou Y, Liu J, Hu C, Huang H, Ren Y, Yu W, Guo Y, Zhang YY, Zhou Y. AFP specificity for HCC surveillance is increased by mitigating liver injury among treated chronic hepatitis B patients with elevated AFP. *Int J Clin Exp Pathol* 2019; **12**: 1315-1323 [PMID: 31933945]

63 **Peng C**, Li Z, Xie Z, Wang Z, Ye Y, Li B, Li W. The role of circulating microRNAs for the diagnosis of hepatitis B virus-associated hepatocellular carcinoma with low alpha-fetoprotein level: a systematic review and meta-analysis. *BMC Gastroenterol* 2020; **20**: 249 [PMID: 32736604 DOI: 10.1186/s12876-020-01345-5]

64 **Shen Q**, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, Wang N, Niu Y, Wu Z, Zhou J, Qiu SJ, Shi YH, Yu B, Tang N, Chu W, Wang M, Wu J, Zhang Z, Yang S, Gu J, Wang H, Qin W. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. *Lancet Oncol* 2012; **13**: 817-826 [PMID: 22738799 DOI: 10.1016/S1470-2045(12)70233-4]

65 **Inoue T**, Tanaka Y. Novel biomarkers for the management of chronic hepatitis B. *Clin Mol Hepatol* 2020; **26**: 261-279 [PMID: 32536045 DOI: 10.3350/cmh.2020.0032]

66 **Ekpanyapong S**, Reddy KR. Hepatitis B Virus Reactivation: What Is the Issue, and How Should It Be Managed? *Clin Liver Dis* 2020; **24**: 317-333 [PMID: 32620274 DOI: 10.1016/j.cld.2020.04.002]

67 **Chang ML**, Liaw YF. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management. *J Hepatol* 2014; **61**: 1407-1417 [PMID: 25178562 DOI: 10.1016/j.jhep.2014.08.033]

68 **Chu CW**, Hwang SJ, Luo JC, Lai CR, Tsay SH, Li CP, Wu JC, Chang FY, Lee SD. Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C. *J Clin Gastroenterol* 2001; **32**: 240-244 [PMID: 11246354 DOI: 10.1097/00004836-200103000-00014]

69 **Chen TM**, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. *J Gastroenterol Hepatol* 2007; **22**: 669-675 [PMID: 17444854 DOI: 10.1111/j.1440-1746.2007.04898.x]

70 **Yang N**, Li Z, Yan M, Xiao W, Zhang W, Long Y, Cheng Y, Ming K, Xu B. Evaluation of Serum Alpha-Fetoprotein Level in Chronic Hepatitis C Patients. *Clin Lab* 2019; **65** [PMID: 30775893 DOI: 10.7754/Clin.Lab.2018.180607]

71 **Di Bisceglie AM**, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok AS, Lee WM, Morgan TR, Ghany MG, Gretch DR; HALT-C Trial Group. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. *J Hepatol* 2005; **43**: 434-441 [PMID: 16136646 DOI: 10.1016/j.jhep.2005.03.019]

72 **Fouad R**, Elsharkawy A, Abdel Alem S, El Kassas M, Alboraie M, Sweedy A, Afify S, Abdellatif Z, Khairy M, Esmat G. Clinical impact of serum α-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals. *Eur J Gastroenterol Hepatol* 2019; **31**: 1129-1134 [PMID: 30896550 DOI: 10.1097/MEG.0000000000001400]

73 **Noritake H**, Kobayashi Y, Ooba Y, Kitsugi K, Shimoyama S, Yamazaki S, Chida T, Watanabe S, Kawata K, Suda T. Improved Serum Alpha-Fetoprotein Levels after Iron Reduction Therapy in HCV Patients. *ISRN Hepatol* 2014; **2014**: 875140 [PMID: 27335844 DOI: 10.1155/2014/875140]

74 **Pennisi G**, Celsa C, Giammanco A, Spatola F, Petta S. The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. *Int J Mol Sci* 2019; **20** [PMID: 31717576 DOI: 10.3390/ijms20225613]

75 **Singal AG**, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. *J Hepatol* 2020; **72**: 250-261 [PMID: 31954490 DOI: 10.1016/j.jhep.2019.08.025]

76 **Lim J**, Singal AG. Surveillance and Diagnosis of Hepatocellular Carcinoma. *Clin Liver Dis (Hoboken)* 2019; **13**: 2-5 [PMID: 30911378 DOI: 10.1002/cld.761]

77 **Sumida Y**, Yoneda M, Seko Y, Ishiba H, Hara T, Toyoda H, Yasuda S, Kumada T, Hayashi H, Kobayashi T, Imajo K, Yoneda M, Tada T, Kawaguchi T, Eguchi Y, Oeda S, Takahashi H, Tomita E, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. *Diagnostics (Basel)* 2020; **10** [PMID: 32785100 DOI: 10.3390/diagnostics10080579]

78 **Babalı A**, Cakal E, Purnak T, Bıyıkoğlu I, Cakal B, Yüksel O, Köklü S. Serum α-fetoprotein levels in liver steatosis. *Hepatol Int* 2009; **3**: 551-555 [PMID: 19890679 DOI: 10.1007/s12072-009-9156-8]

79 **Best J**, Bechmann LP, Sowa JP, Sydor S, Dechêne A, Pflanz K, Bedreli S, Schotten C, Geier A, Berg T, Fischer J, Vogel A, Bantel H, Weinmann A, Schattenberg JM, Huber Y, Wege H, von Felden J, Schulze K, Bettinger D, Thimme R, Sinner F, Schütte K, Weiss KH, Toyoda H, Yasuda S, Kumada T, Berhane S, Wichert M, Heider D, Gerken G, Johnson P, Canbay A. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. *Clin Gastroenterol Hepatol* 2020; **18**: 728-735.e4 [PMID: 31712073 DOI: 10.1016/j.cgh.2019.11.012]

80 **Arrieta O**, Cacho B, Morales-Espinosa D, Ruelas-Villavicencio A, Flores-Estrada D, Hernández-Pedro N. The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. *BMC Cancer* 2007; **7**: 28 [PMID: 17288606 DOI: 10.1186/1471-2407-7-28]

81 **Kobeisy MA**, Morsy KH, Galal M, Sayed SK, Ashmawy MM, Mohammad FM. Clinical significance of elevated alpha-foetoprotein (AFP) in patients with chronic hepatitis C without hepatocellular carcinoma in upper EGYPT. *Arab J Gastroenterol* 2012; **13**: 49-53 [PMID: 22980591 DOI: 10.1016/j.ajg.2012.06.004]

82 **Bayati N**, Silverman AL, Gordon SC. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. *Am J Gastroenterol* 1998; **93**: 2452-2456 [PMID: 9860408 DOI: 10.1111/j.1572-0241.1998.00703.x]

83 **Harada T**, Shigeta K, Noda K, Fukumoto Y, Nishimura H, Mizuta M, Takemoto T. Clinical implications of alpha-fetoprotein in liver cirrhosis: five-year follow-up study. *Hepatogastroenterology* 1980; **27**: 169-175 [PMID: 6161869]

84 **Manuc D**, Preda CM, Sandra I, Baicus C, Cerban R, Constantinescu I, Olteanu AO, Ciora CA, Manuc T, Chiriac DE, Chifulescu AE, Diculescu M, Tieranu C, Negreanu L, Oprea-Calin G, Manuc M. Signification of Serum Alpha-Fetoprotein Levels in Cases of Compensated Cirrhosis and Hepatitis C Virus without Hepatocellular Carcinoma. *J Med Life* 2020; **13**: 68-74 [PMID: 32341704 DOI: 10.25122/jml-2019-0076]

85 **Tzartzeva K**, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, Waljee AK, Singal AG. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. *Gastroenterology* 2018; **154**: 1706-1718.e1 [PMID: 29425931 DOI: 10.1053/j.gastro.2018.01.064]

86 **Parikh ND**, Singal AG, Hutton DW, Tapper EB. Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms. *Am J Gastroenterol* 2020; **115**: 1642-1649 [PMID: 32530829 DOI: 10.14309/ajg.0000000000000715]

87 **Kubota N**, Fujiwara N, Hoshida Y. Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk. *J Clin Med* 2020; **9** [PMID: 33256232 DOI: 10.3390/jcm9123843]

88 **Li X**, Alexander S. Hereditary persistence of alpha-fetoprotein. *Pediatr Blood Cancer* 2009; **52**: 403-405 [PMID: 18985745 DOI: 10.1002/pbc.21816]

89 **Jeon Y**, Choi YS, Jang ES, Kim JW, Jeong SH. Persistent α-Fetoprotein Elevation in Healthy Adults and Mutational Analysis of α-Fetoprotein Promoter, Enhancer, and Silencer Regions. *Gut Liver* 2017; **11**: 136-141 [PMID: 27609486 DOI: 10.5009/gnl16069]

90 **Schefer H**, Mattmann S, Joss RA. Hereditary persistence of alpha-fetoprotein. Case report and review of the literature. *Ann Oncol* 1998; **9**: 667-672 [PMID: 9681083 DOI: 10.1023/a:1008243311122]

91 **Greenberg F**, Rose E, Alpert E. Hereditary persistence of alpha-fetoprotein. *Gastroenterology* 1990; **98**: 1083-1085 [PMID: 1690155 DOI: 10.1016/0016-5085(90)90037-2]

92 **Alj Y**, Milgrom E, Guiochon-Mantel A. Rapid determination of alpha-fetoprotein gene promoter mutations in hereditary persistence of alpha-fetoprotein. *Clin Chem* 2004; **50**: 1706-1707 [PMID: 15331517 DOI: 10.1373/clinchem.2004.034157]

93 **Blesa JR**, Vidal J, Giner-Durán R, Lacalle ML, Catalán I, Hernández-Yago J. Detection of hereditary persistence of alpha-fetoprotein by conformation-sensitive gel electrophoresis analysis. *Clin Chem* 2003; **49**: 2102-2103 [PMID: 14633890 DOI: 10.1373/clinchem.2003.024232]

94 **Bonfig W**, Hempel M, Teichert-von Lüttichau I, Liptay S, Burdach S. Avoiding harmful procedures in patients with elevated α-fetoprotein concentrations: hereditary persistence of α-fetoprotein is an important and benign differential diagnosis!. *J Pediatr Hematol Oncol* 2012; **34**: e301-e303 [PMID: 22430587 DOI: 10.1097/MPH.0b013e3182441256]

95 **McVey JH**, Michaelides K, Hansen LP, Ferguson-Smith M, Tilghman S, Krumlauf R, Tuddenham EG. A G-->A substitution in an HNF I binding site in the human alpha-fetoprotein gene is associated with hereditary persistence of alpha-fetoprotein (HPAFP). *Hum Mol Genet* 1993; **2**: 379-384 [PMID: 7684942 DOI: 10.1093/hmg/2.4.379]

96 **Houwert AC**, Giltay JC, Lentjes EG, Lock MT. Hereditary persistence of alpha-fetoprotein (HPAF P): review of the literature. *Neth J Med* 2010; **68**: 354-358 [PMID: 21116028]

**Footnotes**

**Conflict-of-interest statement:** There is no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** October 4, 2021

**First decision:** October 20, 2021

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** El-Sokkary AM, Song L **S-Editor:** Fan JR **L-Editor:** A **P-Editor:** Fan JR

**Figure**



**Figure 1 ELISA measures.** A: ELISA measures alpha-fetoprotein (AFP) by detecting reactivity with two anti-AFP antibodies; B: Interfering antibodies that bind directly to the capture and detect reagents without the target AFP (no analytes). This binding would emit light and become luminescent causing false positive results and high values; C: Interfering antibodies can inhibit reactivity of the ELISA by binding to the reagents and prevent the detection of AFP by the anti-AFP antibodies; that leads to a false negative result. AFP: Alpha-fetoprotein.

**Table 1 Causes of alpha-fetoprotein elevation[13-15]**

|  |  |
| --- | --- |
| **Hepatic** | **Non-hepatic** |
| **Neoplastic** | **Neoplastic** |
| Hepatocellular carcinoma | Germ cell tumors (testicular and ovarian malignancies) |
| Intrahepatic cholangiocarcinoma | Gastric cancer |
| **Non-neoplastic** | **Non-neoplastic** |
| Liver cirrhosis | Normal pregnancy/infancy |
| Fulminant acute hepatitis | Colitis |
| Acute and chronic viral hepatitis | Fetal disorders (Gastroschisis, Neural tube defect) |
| Chronic liver diseases | Ataxia telangiectasia |
| Biliary obstruction (Intrahepatic and extrahepatic causes) | Hereditary tyrosinemia type 1 |
| Drug induced hepatitis | Hereditary AFP persistence |
| Alcohol liver disease | Beckwith-Wiedemann syndrome |
| Non-alcoholic liver disease | Systemic lupus erythematosus |
| Neonatal hepatitis | Hirschsprung’s disease |
| Massive hepatic necrosis |  |
| Wilson disease |  |
| Hemochromatosis |  |

AFP: Alpha-fetoprotein.

**Table 2 Sensitivity and specificity of alpha-fetoprotein at different cut-off values[22-24]**

|  |  |  |
| --- | --- | --- |
| **AFP cut-off value** | **Sensitivity** | **Specificity** |
| 20 | Approximately 60% | 90% |
| 50 | 47% | 96% |
| 100 | 31.2% | 98.8% |
| 400 | 17% | 99.4% |

AFP: Alpha-fetoprotein.

**Table 3 Overview of the diagnostic parameters for hepatocellular carcinoma**

|  |  |  |
| --- | --- | --- |
| **Diagnostic parameter (cut off)** | **Remark** | **AUROC** |
| AFP (> 20 ng/mL) | Sensitivity: 40%–65% | 0.54–0.80 |
| Specificity: 76%–96% |
| AFP-L3 (> 15%) | Sensitivity: 45%–90% | 0.74–0.84 |
| Specificity: 95% |
| AFP-L3 + AFP-P4 + P5 (> 15% for both biomarkers) | Sensitivity: 55.3%–61% | 0.76 |
| Specificity: 82.3%–93.9% |
| AFP, AFP-L3 and DCP (3-25 ng/mL, 1%-10%, 0.48 ng/mL or 40 mAu/mL) | Sensitivity: 81%–93% | 0.88–0.93 |
| Specificity: 69%-87% |
| AFP and GP73 | Sensitivity: 75%-91% | 0.91–0.95 |
| Specificity: 81%-97% |

AFP: Alpha-fetoprotein; DCP: Des-gamma-carboxyprothrombin.